Purpose of Review

In this review, the impact of obesity on cardiovascular disease in women and emerging anti-obesity pharmacologic treatments are discussed.

Recent Findings

Robust evidence demonstrates the burden of obesity across the lifespan in women and links obesity to a diverse set of cardiovascular diseases. Female-specific risk factors including sex hormones and pregnancy factors intersect with obesity and cardiovascular risk. Sustained weight loss has potential for cardiovascular benefits. Recent trials demonstrate cardiovascular benefits of emerging agents with weight loss effects including GLP-1 RA and SGLT2 inhibitors in women.

Summary

Treatment and prevention strategies for cardiovascular disease in obese women should include integration of weight management strategies including the targeted use of emerging pharmacologic therapies.

中文翻译：

---

治疗患有心血管疾病的女性肥胖的新兴医学疗法

审查目的

在这篇综述中，讨论了肥胖对女性心血管疾病的影响以及新兴的抗肥胖药物治疗。

最近的发现

强有力的证据表明肥胖对女性的整个生命周期造成负担，并将肥胖与多种心血管疾病联系起来。女性特有的危险因素，包括性激素和妊娠因素，与肥胖和心血管风险相交叉。持续减肥有可能对心血管有益。最近的试验表明，具有减肥作用的新兴药物（包括 GLP-1 RA 和 SGLT2 抑制剂）对女性具有心血管益处。

概括

肥胖女性心血管疾病的治疗和预防策略应包括体重管理策略的整合，包括有针对性地使用新兴药物疗法。